Small Cell Lung Cancer
Small Cell Lung Cancer
Advertisement
Cecilia BrownSmall Cell Lung Cancer | September 30, 2024
The results of the phase 3 NRG Oncology/Alliance LU005 trial were presented during the 2024 ASTRO Annual Meeting.
Read More
Molly Li, MBBSESMO 2024: Focus on Lung Cancer | September 17, 2024
Dr. Li discusses important thoracic oncology data presented at the ESMO 2024 Congress, which was held in Barcelona, Spain
Ken Culver, MDWCLC 2024 | September 17, 2024
Ken Culver, MD, Director of Research and Clinical Affairs at ALK Positive, discusses the on-going ALK Life Study.
Cecilia BrownNon-Small Cell Lung Cancer | September 13, 2024
The subcutaneous injection is now approved for all adult indications of the intravenous formulation of atezolizumab
Balazs Halmos, MDWCLC 2024 | September 13, 2024
Dr. Halmos weighs in on HARMONi-2, TROPION-Lung 01, the SOHO-01 and Beamion LUNG-1 studies, and more.
Martin Reck, MD, PhDESMO 2024: Focus on Lung Cancer | September 12, 2024
Martin Reck, MD, PhD, shares his insights on key data in lung cancer to be presented at the ESMO Congress 2024.
Narjust Florez, MD, FASCOWCLC 2024 | September 9, 2024
Narjust Florez, MD, FASCO, discusses meeting highlights, the IASLC 50th Anniversary Celebration, research, and more.
Lung Cancers Today EditorsWCLC 2024 | September 8, 2024
More than one-third of patients with platinum-resistant ES-SCLC responded to treatment.
Katie KoskoNon-Small Cell Lung Cancer | August 30, 2024
Researchers used data from the Thoracic Tumors Registry to conduct 2 analyses using artificial intelligence.
Katie KoskoLung Cancer | August 29, 2024
The intervention included psychoeducation, relaxation training, and behavioral techniques for managing acute breathlessness.
Martin Reck, MD, PhDSmall Cell Lung Cancer | September 4, 2024
Dr. Reck discusses why the research represents important progress in treating patients with extensive-stage SCLC.
Eric Singhi, MDWCLC 2024 | August 27, 2024
Eric Singhi, MD, shares what he's most looking forward to at the upcoming ISALC 2024 World Conference on Lung Cancer.
Eric Singhi, MDWCLC 2024 | August 23, 2024
Eric Singhi, MD, discusses the key milestone that will be celebrated at the conference, which will be held in San Diego.
David P. Carbone, MD, PhDLung Cancer | August 22, 2024
Learn how clinicians can take practical steps to ensure patients with lung cancer receive comprehensive biomarker testing.
Cecilia BrownSmall Cell Lung Cancer | August 21, 2024
The trial has been discontinued based on the recommendations of an independent data monitoring committee.
Cecilia BrownSmall Cell Lung Cancer | August 19, 2024
The initiation of the trial is based on updated results from a subgroup analysis of the phase 1/2 IDeate-PanTumor01 trial.
David P. Carbone, MD, PhDLung Cancer | August 16, 2024
Recent data show that less than half of patients are receiving biomarker testing results before starting treatment.
Cecilia BrownSmall Cell Lung Cancer | August 15, 2024
The regulatory action is based on data from the phase 3 ADRIATIC trial.
Luis Paz-Ares, MD, PhDSmall Cell Lung Cancer | August 13, 2024
Dr. Paz-Ares shares his insights on recent studies and highlights practice-changing data in lung cancer.
Cecilia BrownSmall Cell Lung Cancer | August 9, 2024
Trilaciclib is an FDA-approved agent that protects hematopoietic stem cells from chemotherapy-induced myelosuppression.
Advertisement
Advertisement
Advertisement
Latest News

October 3, 2024